Portfolio company
Invirsa
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops topical eye drops to treat ocular conditions and DNA damage for patients with diseases like conjunctivitis and dry eye.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
INEYE Therapeutics
This company develops ocular drug delivery inserts to treat chronic eye conditions such as dry eye and glaucoma for patients.
Eyexora
This company develops therapeutics and medical devices for ophthalmic diseases to treat patients with vision-threatening conditions.
Healome Therapeutics
The company develops eye-drop matrix technology to improve drug delivery and treatment for patients with ocular surface diseases.
Envisia
This clinical-stage biotechnology company develops extended-release ocular therapies for patients with glaucoma and other eye disorders.
Ikarovec
This company develops bicistronic gene therapies to treat chronic ophthalmic diseases, such as age-related macular degeneration, for patients suffering from vision loss.
PulseSight Therapeutics
This company develops non-viral gene therapies for patients with severe eye diseases including age-related macular degeneration.
Iolyx Therapeutics
The company develops immunomodulatory medicines to treat ocular inflammation and autoimmune eye diseases for patients worldwide.
Perfuse Therapeutics
The company develops sustained-release intravitreal therapies to treat ischemia-driven ocular diseases for patients with conditions like glaucoma and diabetic retinopathy.